Essential CNS drug developmentcedited

"Central Nervous System disorders have an enormous impact on individuals and on society as a whole. The development of better treatments is crucial and is a major focus of pharmaceutical and biotechnology companies. This book explains the complicated process of CNS drug development in a way tha...

Full description

Saved in:
Bibliographic Details
Other Authors: Kalali, Amir (Editor), Preskorn, Sheldon (Editor), Kwentus, Joseph (Editor), Stahl, Stephen M. (Editor)
Format: Book
Language:English
Published: Cambridge Cambridge University Press 2012
Series:Cambridge medicine
Subjects:
Online Access:Click Here to View Status and Holdings.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000nam a2200000#i 4501
001 wils-476418
005 2020118121211
008 220819t2012 -UK af #001 deng D
020 # # |a 9780521766067  |q hardback 
020 # # |a 0521766060  |q hardback 
040 # # |a DNLM  |c DNLM  |d UiTM  |e rda 
041 0 # |a English 
060 0 0 |a QV 76.5 
090 0 0 |a QV76.5  |b E785 2012 
245 0 0 |a Essential CNS drug developmentcedited  |c Edited by Amir Kalali , Sheldon Preskorn , Joseph Kwentus , Stephen M. Stahl 
264 # 1 |a Cambridge  |b Cambridge University Press  |c 2012 
264 # 4 |c ©2012 
300 # # |a x, 207 pages  |b illustrations  |c 24 cm 
336 # # |a text  |b txt  |2 rdacontent 
337 # # |a unmediated  |b n  |2 rdamedia 
338 # # |a volume  |b nc  |2 rdacarrier 
490 1 # |a Cambridge medicine 
504 # # |a Includes bibliographical references and index 
505 8 # |a Machine generated contents note: History of CNS drug development / Sheldon H. Preskorn -- Regulatory issues / Gwen L. Zornberg -- Pre-clinical development / Alan J. Cross and Frank D. Yocca -- Phase I trials: from traditional to newer approaches / Matthew Macaluso, Michael Krams and Sheldon H. Preskorn -- Phase II development and the path to personalized medicine in CNS disease / Douglas E. Feltner and Kenneth R. Evans -- CNS drug development - Phase III / Judith Dunn, Penny Randall and Amir Kalali / Statistics issues relevant to CNS drug development / Craig H. Mallinckrodt, William R. Prucka and Geert Molenberghs -- Clinical trials management at company level / Nuala Murphy -- Clinical trials management at the site level / Joseph Kwentus -- Medical writing for CNS indications / Ginette Nachman -- Dissemination of clinical trial information: multiple audiences, multiple formats / Leslie Citrome -- The importance of treating cognition in schizophrenia and other severe mental illnesses: background, strategies, and findings to date / Philip D. Harvey and Richard S. E. Keefe -- Leveraging disruptive technologies to drive innovation in CNS clinical drug development / Penny Randall, Judith Dunn and Amir Kalali. 
520 # # |a "Central Nervous System disorders have an enormous impact on individuals and on society as a whole. The development of better treatments is crucial and is a major focus of pharmaceutical and biotechnology companies. This book explains the complicated process of CNS drug development in a way that is engaging for any interested professional or student. Chapters cover each stage of drug development, from pre-clinical research through all phases of clinical trials, to reporting to the regulatory authorities. Other key issues covered include strategic considerations, regulatory constraints, dissemination of results and ethical considerations. The user-friendly format and style enable readers to find important information quickly and easily. Written and edited by experts from different sectors actively engaged in CNS drug development, this is a unique resource for drug developers, investigators, academics and clinicians"--Provided by publisher. 
650 1 2 |a Central Nervous System Agents  |x pharmacology 
650 2 2 |a Clinical Trials as Topic  |x methods 
650 2 2 |a Drug Evaluation  |x methods 
650 2 2 |a Drug Evaluation, Preclinical  |x methods 
700 1 # |a Kalali, Amir  |e editor 
700 1 # |a Preskorn, Sheldon  |e editor 
700 1 # |a Kwentus, Joseph  |e editor 
700 1 # |a Stahl, Stephen M.  |e editor 
830 0 # |a Cambridge medicine 
856 4 0 |z Click Here to View Status and Holdings.  |u https://opac.uitm.edu.my/opac/detailsPage/detailsHome.jsp?tid=476418 
964 # # |c BOK  |d MD